GleamWall
中文EN

HRGN Harvard Apparatus Regenerative Technology, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1563665 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY35.1%
TTM net income YoY1.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin7.5%
Operating margin-643.0%
Net margin-642.0%
FCF margin—
EBITDA margin-642.6%

Returns

ROE-621.0%
ROA-225.6%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets83.5%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-269.00x

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-127.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$145,000$414,000$226,000$219,000$123,000$317,000$45,000$258,000
Cost of revenue$133,000$391,000$206,000$199,000$112,000$302,000$33,000$175,000
Gross profit$12,000$23,000$20,000$20,000$11,000$15,000$12,000$83,000
R&D expense$218,000$948,000$563,000$700,000$655,000$697,000$601,000$271,000
SG&A expense$1.24M$751,000$1.04M$986,000$1.04M$1.15M$1.07M$1.08M
Operating income-$1.46M-$1.69M-$1.61M-$1.70M-$1.71M-$1.83M-$1.67M-$1.36M
Interest expense$13,000$8,000$2,000$1,000$2,000$3,000$2,000$2,000
Income tax$0$0$0$0$0$0$0—
Net income-$1.46M-$1.70M-$1.60M-$1.69M-$1.70M-$1.82M-$1.66M-$1.34M
EBITDA-$1.46M-$1.69M-$1.60M-$1.70M-$1.71M-$1.83M-$1.67M-$1.36M
EPS (basic)-0.08-0.10-0.09—-0.10-0.11-0.10—
EPS (diluted)————————
Balance sheet
Cash & equivalents$1.85M$351,000$419,000$1.35M$1.32M$786,000$1.73M$2.49M
Receivables$18,000$9,000$16,000$16,000$3,000$5,000$4,000$231,000
Inventory$0$0$15,000$16,000$22,000$27,000$48,000$80,000
Current assets$2.30M$789,000$873,000$1.83M$1.63M$1.12M$2.30M$3.23M
PP&E, net$3,000$4,000$5,000$6,000$7,000$8,000$9,000$11,000
Total assets$3.17M$1.69M$1.80M$2.68M$2.55M$2.14M$3.42M$4.44M
Current liabilities$2.65M$3.04M$1.65M$1.53M$876,000$1.23M$1.20M$1.02M
Total liabilities$2.65M$3.06M$1.71M$1.62M$992,000$1.38M$1.37M$1.22M
Shareholders' equity$522,000-$1.38M$92,000$1.06M$1.55M$761,000$2.05M$3.22M
Shares outstanding20.09M17.58M17.58M17.58M17.17M15.92M15.92M15.92M
Cash flow statement
Operating cash flow-$621,000-$569,000-$937,000-$664,000-$1.47M-$941,000-$758,000-$1.12M
Financing cash flow$2.12M——$700,000$2.00M$0$0$0
Depreciation & amortization$1,000$1,000$1,000$1,000$1,000$1,000$2,000$2,000
Stock-based compensation$700,000$200,000$632,000$493,000$500,000$500,000$485,000$708,000

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.